At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 127 enrolled
Drug / intervention
Pulmicortdrug
Likely dose
Pulmicort 180mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Determining Mechanisms of Asthma Through Detailed Analysis of Airway Secretions and Tissues
In Brief
A Phase 1 clinical trial evaluating Pulmicort for Asthma. Completed, enrolled 127 participants across 1 site.
Detailed Summary
The purpose of this study is to identify the causes of asthma that were not previously suspected, to better understand the effects of inhaled steroids on asthma and to identify new way to treat asthma. In order to take advantage of the most current scientific expertise, we (scientists at UCSF) plan to work together with Genentech Inc. We believe that working with Genentech will provide the best chance of developing new treatments for asthma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited States
CollaboratorsGenentech, Inc.
Timeline
Phase 1CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2007
First PostedJan 2008
Primary CompletionJun 2011
TodayJul 2026
First PostedJan 16, 2008
Enrollment StartApr 1, 2007
Primary CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 18.5 years ago
Interventions
Pulmicortdrug
inhaled powder of inhaled corticosteroid, 1 puff (180mcg) twice a day for 8-10 weeks